News
DVAX
13.00
+0.04%
0.01
Weekly Report: what happened at DVAX last week (0219-0223)?
Weekly Report · 2d ago
Dynavax’s Strong Financial Outlook and Heplisav-B Market Expansion Prompt ‘Buy’ Rating
Analyst Edward White from H.C. Wainwright reiterated a Buy rating on the stock and has a $29.00 price target. Dynavax is expected to be cash-flow positive in 2024. The company's Heplisav-B Hepatitis B vaccine has gained market share in the U.S.
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX) and EDAP TMS (EDAP)
TipRanks · 5d ago
Dynavax Technologies: A Stable Hold Amidst a Catalyst-Deficient Forecast
TipRanks · 5d ago
Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating
TipRanks · 5d ago
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies (DVAX) announces its fourth quarter and full year 2023 financial results conference call. Ryan Spencer, chief executive officer of Dynavax, will discuss the company's results. The company will also discuss its outlook for the hepatitis B vaccine market in 2024.
The Motley Fool · 5d ago
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
NASDAQ · 5d ago
Dynavax Technologies: Q4 Earnings Insights
Dynavax Technologies reported its Q4 earnings on February 22, 2024. The company missed its earnings estimate by 100.0%. The company's revenue was down $128.90 million from the same period last year. Last quarter the company beat on EPS by $0.11.
Benzinga · 5d ago
Dynavax Technologies Q4 Sales $55.60M Beat $52.73M Estimate
Benzinga · 5d ago
Earnings Scheduled For February 22, 2024
Bausch Health Companies is expected to report quarterly earnings at $1.02 per share on revenue of $2.30 billion. Indivior is likely to report earnings for its fourth quarter. Other companies are expected to be reporting before the bell on Monday, December 11.
Benzinga · 6d ago
Weekly Report: what happened at DVAX last week (0212-0216)?
Weekly Report · 02/19 09:31
Small cap value stocks with potential M&A candidacy - BofA
BofA Securities has updated its small-cap value stocks that are potential mergers and acquisitions candidates. The small cap value stocks are from the Russell 2000. Mergers and deals have picked up in several sectors, particularly in health care. There is more potential for sectors such as staples and banks.
Seeking Alpha · 02/16 16:10
First Week of October 18th Options Trading For Dynavax Technologies (DVAX)
NASDAQ · 02/16 16:03
Dynavax Technolo: Statement of changes in beneficial ownership of securities
Press release · 02/14 16:07
Analysts See 25% Upside For PSCH
NASDAQ · 02/12 15:26
Weekly Report: what happened at DVAX last week (0205-0209)?
Weekly Report · 02/12 09:28
More
Webull provides a variety of real-time DVAX stock news. You can receive the latest news about Dynavax Technolo through multiple platforms. This information may help you make smarter investment decisions.
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B vaccine and CpG 1018. Its HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. It is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, which are focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza, and universal influenza.